15 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 15 of 15 clinical reviews.
A clinician-reviewed guide for teens aged 12-17 taking Dayvigo (lemborexant) covering next-morning grogginess, school performance, sports safety, driving eligibility, and dose timing strategies.
A clinician-reviewed guide for caregivers administering Dayvigo (lemborexant) to adolescents aged 12 to 17, covering dosing, timing, safety, and monitoring based on FDA labeling and clinical evidence.
Everything clinicians and caregivers need to know about transitioning adolescents (ages 12-17) on Dayvigo (lemborexant) to adult insomnia care, including dosing continuity, monitoring, and guideline-based decision points.
A physician-reviewed guide to how lemborexant (Dayvigo) affects sleep architecture, brain development, hormones, and academic performance in adolescents ages 12 to 17, with dosing guidance and safety data.
A clinician-reviewed guide to lemborexant (Dayvigo) use in patients aged 65 and older, covering pharmacokinetics, trial evidence, fall risk, cognitive effects, and prescribing considerations for geriatric insomnia.
A clinician-focused guide to lemborexant (Dayvigo) for patients 65 and older, covering pharmacokinetics, dosing, fall risk, drug interactions, and how to manage care transitions safely in geriatric populations.
A clinical review of lemborexant (Dayvigo) use in patients aged 65 and older, covering FDA-approved dosing, off-label applications, safety data from SUNRISE-2, fall risk, drug interactions, and practical prescribing guidance for geriatric insomnia.
A clinician-reviewed guide to lemborexant (Dayvigo) use in older adults, covering next-day sedation, fall risk, driving, physical activity, and cognitive effects relevant to geriatric patients.
A clinician-reviewed breakdown of lemborexant (Dayvigo) use in pediatric patients under age 12, covering developmental safety, orexin system biology, current FDA status, and what the evidence actually shows.
A clinical review of off-label lemborexant use in pediatric patients under age 12, covering FDA approval status, available trial data, safety signals, and guidance for clinicians considering this dual orexin receptor antagonist in young children.
A clinical review of lemborexant off-label prescribing in adolescents ages 12 to 17, covering evidence, dosing considerations, safety, and how it compares to approved pediatric sleep options.
Complete caregiver guide to Dayvigo (lemborexant) in children under 12, covering FDA approval status, dosing, safety data, administration steps, and when to call the prescriber.
Complete caregiver guide for giving lemborexant (Dayvigo) to adults 65 and older: correct dosing, fall prevention, swallowing tips, drug interactions, and when to call the prescriber.
A clinical guide to transitioning young patients from pediatric to adult care while on lemborexant (Dayvigo), covering FDA approval status, pharmacology, safety monitoring, and practical handoff protocols.
A clinician-reviewed guide to lemborexant (Dayvigo) use in children under 12, covering school performance, daytime sedation, physical activity safety, and practical management strategies for caregivers.